MedKoo Cat#: 530479 | Name: Dexamethasone phosphate disodium
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexamethasone phosphate disodium is a water-soluble form of the synthetic glucocorticoid dexamethasone.

Chemical Structure

Dexamethasone phosphate disodium
Dexamethasone phosphate disodium
CAS#2392-39-4 (phosphate sodium)

Theoretical Analysis

MedKoo Cat#: 530479

Name: Dexamethasone phosphate disodium

CAS#: 2392-39-4 (phosphate sodium)

Chemical Formula: C22H28FNa2O8P

Exact Mass: 0.0000

Molecular Weight: 516.41

Elemental Analysis: C, 51.17; H, 5.47; F, 3.68; Na, 8.90; O, 24.78; P, 6.00

Price and Availability

Size Price Availability Quantity
100mg USD 50.00 Ready to ship
1g USD 285.00 Ready to ship
5g USD 450.00 Ready to ship
20g USD 950.00 Ready to ship
50g USD 1,650.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Dexamethasone Phosphate disodium; EGP-437; EGP 437; EGP437. Dex-Phos.
IUPAC/Chemical Name
sodium 2-((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl phosphate
InChi Key
PLCQGRYPOISRTQ-FCJDYXGNSA-L
InChi Code
InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
SMILES Code
C[C@@]12[C@](C(COP([O-])([O-])=O)=O)(O)[C@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O.[Na+].[Na+]
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Dexamethasone reduces levels of activated NF-κB in immature dendritic cells (DCs) and inhibits differentiation into mature DCs. It also induces differentiation of human mesenchymal stem cells (MSCs) and is used in the generation of liver organoids. Dexamethasone induces autophagy in acute lymphoblastic leukemia (ALL) cell lines. Dexamethasone acts as viral transduction enhancer by promoting intracellular shuttling of HIV-1 pre-integration complex to the nucleus.
In vitro activity:
This study suggests that the anti-inflammatory properties of glucocorticoids relate to their ability to transrepress rather than transactivate genes. Dexamethasone inhibited GM-CSF release from A549 cells with an EC50 value of 2.2 x 10(-9) M). Dexamethasone’s (EC50 = 3.6 x 10(-8) M) ability to induce transcription of the beta2-receptor was correlated with GR DNA binding. Dexamethasone’s (IC50=0.5 x 10(-9) M) ability to inhibit a 3 x kappaB was associated with inhibition of GM-CSF release. Reference: Br J Pharmacol. 1999 Jun;127(4):1003-11. https://pubmed.ncbi.nlm.nih.gov/10433509/
In vivo activity:
The administration of low doses of dexamethasone represents a promising adjuvant treatment for pulmonary tuberculosis (TB). In a mice model of progressing TB, dexamethasone administered with conventional antibiotics in late disease stage decreased the lung bacilli load and lung pneumonia, and increased mouse survival. Dexamethasone also decreased the inflammatory response in the SNC and, therefore, sickness behavior and neurological abnormalities in the infected animals. Reference: Microorganisms. 2023 Jun 10;11(6):1554. https://pubmed.ncbi.nlm.nih.gov/37375056/
Solvent mg/mL mM
Solubility
DMSO 1.0 1.94
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 516.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Gao Z, Schwieger J, Matin-Mann F, Behrens P, Lenarz T, Scheper V. Dexamethasone for Inner Ear Therapy: Biocompatibility and Bio-Efficacy of Different Dexamethasone Formulations In Vitro. Biomolecules. 2021 Dec 17;11(12):1896. doi: 10.3390/biom11121896. PMID: 34944539; PMCID: PMC8699596. 2. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003-11. doi: 10.1038/sj.bjp.0702613. PMID: 10433509; PMCID: PMC1566089. 3. Lara-Espinosa JV, Arce-Aceves MF, Barrios-Payán J, Mata-Espinosa D, Lozano-Ordaz V, Becerril-Villanueva E, Ponce-Regalado MD, Hernández-Pando R. Effect of Low Doses of Dexamethasone on Experimental Pulmonary Tuberculosis. Microorganisms. 2023 Jun 10;11(6):1554. doi: 10.3390/microorganisms11061554. PMID: 37375056; PMCID: PMC10305529. 4. LaLone CA, Villeneuve DL, Olmstead AW, Medlock EK, Kahl MD, Jensen KM, Durhan EJ, Makynen EA, Blanksma CA, Cavallin JE, Thomas LM, Seidl SM, Skolness SY, Wehmas LC, Johnson RD, Ankley GT. Effects of a glucocorticoid receptor agonist, dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22. doi: 10.1002/etc.1729. Epub 2012 Feb 6. PMID: 22189798.
In vitro protocol:
1. Gao Z, Schwieger J, Matin-Mann F, Behrens P, Lenarz T, Scheper V. Dexamethasone for Inner Ear Therapy: Biocompatibility and Bio-Efficacy of Different Dexamethasone Formulations In Vitro. Biomolecules. 2021 Dec 17;11(12):1896. doi: 10.3390/biom11121896. PMID: 34944539; PMCID: PMC8699596. 2. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003-11. doi: 10.1038/sj.bjp.0702613. PMID: 10433509; PMCID: PMC1566089.
In vivo protocol:
1. Lara-Espinosa JV, Arce-Aceves MF, Barrios-Payán J, Mata-Espinosa D, Lozano-Ordaz V, Becerril-Villanueva E, Ponce-Regalado MD, Hernández-Pando R. Effect of Low Doses of Dexamethasone on Experimental Pulmonary Tuberculosis. Microorganisms. 2023 Jun 10;11(6):1554. doi: 10.3390/microorganisms11061554. PMID: 37375056; PMCID: PMC10305529. 2. LaLone CA, Villeneuve DL, Olmstead AW, Medlock EK, Kahl MD, Jensen KM, Durhan EJ, Makynen EA, Blanksma CA, Cavallin JE, Thomas LM, Seidl SM, Skolness SY, Wehmas LC, Johnson RD, Ankley GT. Effects of a glucocorticoid receptor agonist, dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22. doi: 10.1002/etc.1729. Epub 2012 Feb 6. PMID: 22189798.
1: Torres MP, Entwistle F, Coote PJ. Effective immunosuppression with dexamethasone phosphate in the Galleria mellonella larva infection model resulting in enhanced virulence of Escherichia coli and Klebsiella pneumoniae. Med Microbiol Immunol. 2016 Aug;205(4):333-43. doi: 10.1007/s00430-016-0450-5. PubMed PMID: 26920133; PubMed Central PMCID: PMC4939170. 2: Patane MA, Schubert W, Sanford T, Gee R, Burgos M, Isom WP, Ruiz-Perez B. Evaluation of ocular and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits. J Ocul Pharmacol Ther. 2013 Oct;29(8):760-9. doi: 10.1089/jop.2012.0175. PubMed PMID: 23844757. 3: Martín-Sabroso C, Tavares-Fernandes DF, Espada-García JI, Torres-Suárez AI. Validation protocol of analytical procedures for quantification of drugs in polymeric systems for parenteral administration: dexamethasone phosphate disodium microparticles. Int J Pharm. 2013 Dec 15;458(1):188-96. doi: 10.1016/j.ijpharm.2013.09.026. PubMed PMID: 24120930. 4: Keeler GD, Durdik JM, Stenken JA. Effects of delayed delivery of dexamethasone-21-phosphate via subcutaneous microdialysis implants on macrophage activation in rats. Acta Biomater. 2015 Sep;23:27-37. doi: 10.1016/j.actbio.2015.05.011. PubMed PMID: 25985913. 5: Keeler GD, Durdik JM, Stenken JA. Localized delivery of dexamethasone-21-phosphate via microdialysis implants in rat induces M(GC) macrophage polarization and alters CCL2 concentrations. Acta Biomater. 2015 Jan;12:11-20. doi: 10.1016/j.actbio.2014.10.022. PubMed PMID: 25449921; PubMed Central PMCID: PMC4717843. 6: Veurink M, Westermaier Y, Gurny R, Scapozza L. Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation. Pharm Res. 2013 Apr;30(4):1176-87. doi: 10.1007/s11095-012-0955-6. PubMed PMID: 23412914. 7: Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013 Aug;19(9):1872-9. doi: 10.1097/MIB.0b013e3182874065. PubMed PMID: 23714676. 8: Cohen AE, Assang C, Patane MA, From S, Korenfeld M; Avion Study Investigators.. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology. 2012 Jan;119(1):66-73. doi: 10.1016/j.ophtha.2011.07.006. PubMed PMID: 22115712. 9: Sharma AK, Sharma HR, Sharma R, Singh A. Comparison of Preoperative Topical Dexamethasone Phosphate Versus Ketorolac Tromethamine in Maintaining Intraoperative Mydriasis During Small Incision Cataract Surgery. J Clin Diagn Res. 2016 May;10(5):NC09-13. doi: 10.7860/JCDR/2016/19590.7863. PubMed PMID: 27437255; PubMed Central PMCID: PMC4948431. 10: Yang K, Weng L, Cheng Y, Zhang H, Zhang J, Wu Q, Xu T. Host-guest chemistry of dendrimer-drug complexes. 6. Fully acetylated dendrimers as biocompatible drug vehicles using dexamethasone 21-phosphate as a model drug. J Phys Chem B. 2011 Mar 17;115(10):2185-95. doi: 10.1021/jp111044k. PubMed PMID: 21338144. 11: Anderson R, Franch A, Castell M, Perez-Cano FJ, Bräuer R, Pohlers D, Gajda M, Siskos AP, Katsila T, Tamvakopoulos C, Rauchhaus U, Panzner S, Kinne RW. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther. 2010;12(4):R147. doi: 10.1186/ar3089. PubMed PMID: 20642832; PubMed Central PMCID: PMC2945041. 12: Smutok MA, Mayo MF, Gabaree CL, Ferslew KE, Panus PC. Failure to detect dexamethasone phosphate in the local venous blood postcathodic lontophoresis in humans. J Orthop Sports Phys Ther. 2002 Sep;32(9):461-8. PubMed PMID: 12322812. 13: Raiskup-Wolf F, Eljarrat-Binstock E, Rehák M, Domb A, Frucht-Pery J. [Transcorneal and transscleral iontophoresis of the dexamethasone phosphate into the rabbit eye]. Cesk Slov Oftalmol. 2007 Sep;63(5):360-8. Slovak. PubMed PMID: 17915587. 14: Sylvestre JP, Díaz-Marín C, Delgado-Charro MB, Guy RH. Iontophoresis of dexamethasone phosphate: competition with chloride ions. J Control Release. 2008 Oct 6;131(1):41-6. doi: 10.1016/j.jconrel.2008.07.002. PubMed PMID: 18662729; PubMed Central PMCID: PMC2574231. 15: Tiebosch IA, Crielaard BJ, Bouts MJ, Zwartbol R, Salas-Perdomo A, Lammers T, Planas AM, Storm G, Dijkhuizen RM. Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats. J Neurochem. 2012 Nov;123 Suppl 2:65-74. doi: 10.1111/j.1471-4159.2012.07945.x. PubMed PMID: 23050644. 16: Castro M, Rossi L, Papadatou B, Bracci F, Knafelz D, Ambrosini MI, Calce A, Serafini S, Isacchi G, D'Orio F, Mambrini G, Magnani M. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Apr;44(4):423-6. PubMed PMID: 17414137. 17: Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, ten Hagen TL, Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 2006 Apr;54(4):1198-208. PubMed PMID: 16575845. 18: Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release. 2005 Sep 2;106(3):386-90. PubMed PMID: 16026884. 19: Anderson CR, Boeh SD, Morris RL, Sembrowich WL, Panus PC. Quantification of total dexamethasone phosphate delivery by iontophoresis. Int J Pharm Compd. 2003 Mar-Apr;7(2):155-9. PubMed PMID: 23979547. 20: Struck HG, Bariszlovich A. Comparison of 0.1% dexamethasone phosphate eye gel (Dexagel) and 1% prednisolone acetate eye suspension in the treatment of post-operative inflammation after cataract surgery. Graefes Arch Clin Exp Ophthalmol. 2001 Oct;239(10):737-42. PubMed PMID: 11760033.